Dr Kenneth S. Korach is the Chief of Reproductive and Developmental Biology Laboratory, at the National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina. He completed his undergraduate studies with a major in Biology from Augusta College and PhD thesis in Endocrinology from Medical College of Georgia, Augusta, Georgia. After working as a research fellow in the laboratory of Dr Lewis Engel at the Harvard Medical School, he joined the NIEHS as a staff fellow in 1976 and since then rose through various academic ranks at the same place. From 1987 to date, he is also the Chief of Receptor Biology Section at the NIEHS. Between 1996 and 2011, he served as the Director of the Environmental Diseases and Medicine Program in the Division of Intramural research at the NIEHS.
Dr Korach has made pioneering contributions to our understanding of estrogen actions in a variety of tissues, using multiple model organisms and a plethora of state of the art biochemical, molecular biology/genomics tools, and novel genetically engineered mouse models. During his accomplished research career, he initially focused on estrogen actions in hypothalamus and pituitary, and then in uterine biology. In 1993, in collaboration with the Nobel prize winner, Professor Oliver Smithies, he published the landmark PNAS paper on estrogen receptor-α null mice. This set the stage for the subsequent and even more high-impact work published in 1994 in the New England Journal of Medicine, identifying a human male patient harboring a homozygous nonsense mutation in the estrogen receptor-α gene. In nearly 300 publications that followed from these fundamental observations, he has provided remarkable physiological and molecular insights into estrogen actions in the pituitary, ovary, uterus, hypothalamic regulation of sexual behavior, spermatogenesis, toxicological effects on reproductive tract development, and extending into non-reproductive organs, including blood vessels, and liver, to name a few.
Dr Korach has been a prolific researcher. His outstanding research work is very highly cited and embodied in more than 350 publications and more than 100 elegantly and authoritatively written book chapters and reviews. He has also edited or co-edited five influential books on reproductive and developmental toxicology and estrogen action. The most collegial quality of Dr Korach is reflected in his generosity to extensively collaborate, and to share his unpublished research work and the most valuable reagents developed in his laboratory.
Dr Korach has given hundreds of keynote seminars and plenary lectures. Most importantly, as the organizer, he has spearheaded several national and international conferences all over the world. His other service highlights include participation in numerous advisory panels, undertaking journal editorial responsibilities, training a number of postdoctoral fellows, and serving on several administration and doctoral thesis committees at the NIEHS. He has won numerous awards and received wide recognition for his research contributions. From the NIH alone, he has received more than dozen awards, including the Outstanding Performance Award (continuously between 1988 and 1995) , the Merit Award, Research Group Merit Award, the Special Service Award, and the Scientist of the Year Award. He received the Pioneer Award from the Frontiers in Reproduction Course, Woods Hole, MA and the prestigious Transatlantic Medal and Dale Medal from the British Endocrine Society. "Ken," as he is dearly called, agreed to do this interview.
Your early work in 1970s on estrogen receptor actions in pituitary and hypothalamus paved the way to your subsequent prolific work on other organs. What led you to switch your focus to uterine biology and foraying into whole animal physiology?
As an endocrinologist, I became interested in translational science and endocrine diseases. So, the best and only way to analyze that research focus was to do whole animal physiology. Molecular biology as we know it today did not exist except in primitive forms, and many basic hormone action studies had to be done as descriptive physiology/endocrinology. Many aspects of hormone action are discovered or identified in cell culture studies, but to actually know if it applies and is relevant in biology you have to test it. Back in the 1970s we knew estrogen-stimulated tissue growth associated with hormonal cancers, but we had no idea of the mechanism or actions to produce those responses. I decided the uterus was a good target tissue to study for that aspect of estrogen hormone action.
After your training at the Harvard Medical
School, what attracted you to the NIEHS and successfully establishing your laboratory there?
I had a couple of offers for positions after my postdoc and decided I could get my career started quicker at NIEHS without having to worry about grants in the beginning. My plan was to get started and stay at NIEHS for a couple of years, get some papers published to establish myself, and then take an academic position. So, when folks visit me, my wife will always bring up the fact that I told her we'd only be at NIEHS for 2 years. So, after 42 years, I am still here and haven't left, although I had some chances to leave. I was recruited to NIEHS when hormonally active environmental substances (now termed endocrine disruptors) were first emerging and the activities were believed to be classified as environmental estrogens. The plan was for me to bring my experience in hormone nuclear receptors as a means toward understanding how these environmental compounds worked. My colleague, John McLachlan, had just identified DES as a potential reproductive toxicant and IARC had listed it as a carcinogen. We collaborated on the hormonal receptor-mediated activities of the DES metabolites isolated by Manfred Metzler. In order to determine the mechanism and how endocrine disruptors were producing their actions, you needed to know the basic mechanism(s) of natural estrogen action. So that was the parallel pattern of my group's research direction. Studies on natural estrogen action applied in some cases to the studies of endocrine disruptors.
You have practically studied every single aspect of estrogen action at the systems-, organ-, cellular, structural/molecular level. What do you think is the most significant contribution you have made?
Foremost was the generation of the original ERKO mice and subsequently the description of the first ER mutant patient. At first, I had tried to identify whether any rodent mouse lines existed that showed the resistance/insensitivity to estrogen as was shown for the tfm mouse described at that time by Wayne Bardin's group with its clinical application to the clinical condition of androgen insensitivity syndrome. Back then, I thought that was some of the strongest evidence that nuclear receptor signaling was mediating physiological hormone actions. However, there was just no mention of an ER mutant rodent line and then we found that it was thought to be a lethal mutation and that probably explained why no line ever existed. Thus, that was the basis for our generation of the ERKO miceit would allow us to know when during development the lethality occurred and might have application to clinical conditions such as fetal death. Therefore, when we actually were successful in generating ERKO mice and then describing the patient, the lethality explanation was now proven wrong. The even more surprising finding was the infertility in the male ERKO mice. That was totally unexpectedthat loss of ER action in a male would produce an infertility phenotype.
Prior to the generation of the ERKO mice were our studies where we described the coupling of membrane growth factor signaling and nuclear receptor action which was novel at the time and has led to ligand-independent nuclear receptor signaling mechanisms which may have application to physiological paracrine signaling that occurs in certain tissues. This is another example where the ERKO mice allowed us to test this concept and find it was valid in uterine stimulation.
Your 1993 PNAS publication is a classic work in the history of estrogen biology. What was it like to collaborate with a pioneer, Dr. Smithies? Did you ever imagine this work with a mouse model will lead to so many breakthrough observations you made?
When I first visited and met Oliver Smithies, he personified the proverbial "English Oxford Professor." He always remained very studious and insightful in our meetings and discussions. I really admired him a great deal, he was quite humble considering his stature and all the discoveries and advancements he had made. It was an honor to have the opportunity to collaborate with him and Dennis Lubahn. I had been a member of Dennis Lubahn's PhD dissertation committee at Duke. We shared an interest in estrogen receptors, and when Dennis was a postdoc with Oliver we jointly convinced him to attempt the gene targeting of the Esr1 gene, which at the time was the only ER gene known. The primary reason Oliver was even interested was that from his earlier studies on atherosclerosis and cardiovascular disease, he knew there was a sex difference in protection for females, and he wanted to know if the effects of estrogen were mediated by the ER. Oliver was always highly focused on cardiovascular disease and genetics. At that time, if there weren't the observed sex differences, I am not sure he would have been much interested in targeting the ER. Fortunately for all of us, he was willing to allow Dennis to conduct the targeting in the Lab. It was a very lengthy process with a significant number of setbacks. The techniques back then were very crude compared to what we have now, with hours of manual screening for the targeted clones. It was just good fortune that Oliver and his expertise recently had joined UNC at the time and it was possible for me to discuss with him in person. Getting Oliver's interest through long distance discussions when he was at Wisconsin probably would not have worked.
You have established many collaborations across different disciplines and nearly all of them resulted in a major publication that provided new insights into estrogen action. What is the secret behind this successful team science approach?
I have had the good fortune to have some excellent colleagues in my group through the years. They all made significant contributions to our group research and collaborative studies. The accomplishments and successes of our group in the various studies have been due to the efforts of the group members and our collaborators and their respective expertise. The collaborative research studies and activities were so broad that it was impossible to conduct the studies at the high level that was needed without the shared interest and dedication of the group members and our collaborators.
Are you currently pursuing any research topic that has remained unsolved for a long time in your laboratory?
YES-besides understanding the physiological activities associated with the global loss of ER action, we would like to know how organ responsiveness might change in different tissues. More importantly is the continuing question of what differences might be apparent from having developmental loss of ER as in the ERKO model compared to a model with inducible KO, where the development is normal with ER expression but then you could generate the KO at a later stage of life. For instance, are some lack of phenotypes in the original ERKO due to some physiological compensation? Folks seem to not appreciate that the ERKO mice never had any ER developmental signaling activities, so it's not possible to answer those types of questions without a later-stage inducible model. Most interesting is the earlier observation of the double ERKO ovarian phenotype reverting from a granulosa cell to a Sertoli cell phenotype only when both ERalpha and ERbeta are KO.
Were you influenced by any at any stage of your career and how did they impact you?
I believe that Jack Gorski, Elwood Jensen, and Jim Clark had a major influence on my remaining in the field of estrogen hormone action with a more focused area of physiological responsiveness to estrogen and trying to determine what aspects of ER action and cellular mechanisms governed the tissue responses. Although in my early career, I studied ER in neuro centers like the pituitary and hypothalamus, the main tissues of study back then were the uterus and mammary gland primarily due to the link to cancer in those tissues. Gorski, Jensen, and Clark were all leaders at that time on estrogen action. As a student and then young investigator, I looked up to all of them for their seminal studies at the time. Therefore, I would have never thought that they would one day become friends and colleagues.
